Nothing Special   »   [go: up one dir, main page]

DK2215119T3 - Monoklonale antistoffer der binder til HGM-CSF og medicinske sammensætninger omfattende de samme. - Google Patents

Monoklonale antistoffer der binder til HGM-CSF og medicinske sammensætninger omfattende de samme.

Info

Publication number
DK2215119T3
DK2215119T3 DK08848696.4T DK08848696T DK2215119T3 DK 2215119 T3 DK2215119 T3 DK 2215119T3 DK 08848696 T DK08848696 T DK 08848696T DK 2215119 T3 DK2215119 T3 DK 2215119T3
Authority
DK
Denmark
Prior art keywords
hgm
csf
bind
same
monoclonal antibodies
Prior art date
Application number
DK08848696.4T
Other languages
English (en)
Inventor
Kenzo Takada
Kantou Nakajima
Barbara Kistler
John Park
Original Assignee
Evec Inc
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evec Inc, Boehringer Ingelheim Int filed Critical Evec Inc
Application granted granted Critical
Publication of DK2215119T3 publication Critical patent/DK2215119T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK08848696.4T 2007-11-13 2008-11-12 Monoklonale antistoffer der binder til HGM-CSF og medicinske sammensætninger omfattende de samme. DK2215119T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007294945 2007-11-13
JP2008052471 2008-02-14
PCT/US2008/012680 WO2009064399A1 (en) 2007-11-13 2008-11-12 Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same

Publications (1)

Publication Number Publication Date
DK2215119T3 true DK2215119T3 (da) 2013-02-04

Family

ID=40329216

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08848696.4T DK2215119T3 (da) 2007-11-13 2008-11-12 Monoklonale antistoffer der binder til HGM-CSF og medicinske sammensætninger omfattende de samme.

Country Status (32)

Country Link
US (2) US8679502B2 (da)
EP (3) EP2535353A1 (da)
KR (1) KR20100102108A (da)
CN (2) CN101970489B (da)
AR (1) AR069290A1 (da)
AU (1) AU2008321429A1 (da)
BR (1) BRPI0820530A2 (da)
CA (1) CA2705539A1 (da)
CL (1) CL2008003361A1 (da)
CO (1) CO6382188A2 (da)
DK (1) DK2215119T3 (da)
EC (1) ECSP10010251A (da)
ES (1) ES2401536T3 (da)
HK (1) HK1146729A1 (da)
HR (1) HRP20130204T1 (da)
IL (1) IL205576A0 (da)
MA (1) MA31899B1 (da)
ME (1) ME01005B (da)
MX (1) MX2010005291A (da)
NZ (2) NZ586027A (da)
PE (1) PE20091420A1 (da)
PL (1) PL2215119T3 (da)
PT (1) PT2215119E (da)
RS (1) RS52713B (da)
RU (2) RU2517596C2 (da)
SG (1) SG176499A1 (da)
SI (1) SI2215119T1 (da)
TN (1) TN2010000210A1 (da)
TW (2) TWI434854B (da)
UY (1) UY31466A1 (da)
WO (1) WO2009064399A1 (da)
ZA (1) ZA201003467B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
AU2008253608A1 (en) * 2007-05-23 2008-11-27 Crc For Asthma And Airways Ltd Neutralizing antibodies
EP2217626A4 (en) * 2007-11-12 2011-06-22 Crc For Asthma And Airways Ltd EPITOP FOR NEUTRALIZING ANTIBODIES
DK2215119T3 (da) 2007-11-13 2013-02-04 Evec Inc Monoklonale antistoffer der binder til HGM-CSF og medicinske sammensætninger omfattende de samme.
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CA2736421A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
CN102271705A (zh) 2008-12-22 2011-12-07 墨尔本大学 骨关节炎治疗
CN108014335A (zh) 2008-12-22 2018-05-11 墨尔本大学 粒细胞巨噬细胞集落刺激因子的拮抗剂的用途
EA201201657A1 (ru) 2010-06-24 2013-06-28 Бёрингер Ингельхайм Интернациональ Гмбх Лечение диабета
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
BR112013033944A2 (pt) 2011-07-06 2017-12-19 Morphosys Ag combinação sinérgica
MA37946B1 (fr) 2012-09-20 2018-09-28 Morphosys Ag Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde
US9833410B2 (en) * 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
WO2014138862A1 (en) * 2013-03-14 2014-09-18 John Schrader Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
ES2860480T3 (es) 2013-08-30 2021-10-05 Takeda Gmbh Anticuerpos neutralizantes de GM-CSF para su uso en el tratamiento de la artritis reumatoide o como analgésicos
US11173208B2 (en) 2014-05-07 2021-11-16 Takeda Gmbh Liquid formulation comprising GM-CSF neutralizing compound
US10618952B2 (en) * 2015-10-30 2020-04-14 Medimmune Limited Prevention of N-terminal truncation in IgG light chains
JP7256116B2 (ja) 2016-09-19 2023-04-11 アイ－エムエービー バイオファーマ （ハンジョウ） カンパニー リミテッド 抗ｇｍ－ｃｓｆ抗体およびその使用
IL271257B1 (en) * 2017-06-25 2024-07-01 Systimmune Inc Multispecific antibodies and methods for their preparation and use
SG11202005273XA (en) * 2017-12-28 2020-07-29 Nanjing Legend Biotech Co Ltd Antibodies and variants thereof against pd-l1
EP3623382A1 (en) * 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US11655293B2 (en) * 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8624899D0 (en) * 1986-10-17 1986-11-19 Sandoz Ltd Monoclonal antibodies
JPH03502582A (ja) * 1988-05-31 1991-06-13 シェリング・バイオテック・コーポレーション 骨髄性白血病の治療方法
AU630496B2 (en) 1989-07-14 1992-10-29 Schering Corporation Antagonists of gm-csf derived from the carboxyl terminus
GB8925590D0 (en) * 1989-11-13 1990-01-04 Central Blood Lab Authority Monoclonal antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
WO1992008474A2 (en) 1990-11-20 1992-05-29 The National Heart & Lung Institute Treatment of lung diseases
CA2060741A1 (en) 1991-02-11 1992-08-12 Robert S. Greenfield Gm-csf inhibiting oligopeptides
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
WO1997014719A1 (en) * 1995-10-16 1997-04-24 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
US5662138A (en) 1996-06-12 1997-09-02 Wang; Wen-Hsing Drop head structure
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
ES2609016T3 (es) 2000-06-16 2017-04-18 Human Genome Sciences, Inc. Anticuerpos que se unen inmunoespecíficamente a BLyS
EP1409530A2 (en) 2000-09-19 2004-04-21 Microbia, Inc. Modulation of secondary metabolite production by zinc binuclear cluster proteins
PE20021080A1 (es) 2001-04-12 2003-02-12 Boehringer Ingelheim Int Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
WO2003040341A2 (en) 2001-11-07 2003-05-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-hepatitis a virus antibodies
ATE444308T1 (de) * 2002-02-13 2009-10-15 Ludwig Inst Cancer Res Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
UA89364C2 (en) 2003-12-03 2010-01-25 Биодженерикс Аг Granulocyte colony stimulating factor peptide conjugate (g-csf)
CA2549409C (en) 2003-12-03 2013-10-29 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
EP1593690B1 (en) 2004-05-05 2009-07-01 Micromet AG Preparation of ScFv antibody fragments
WO2006011353A1 (ja) 2004-07-30 2006-02-02 Thk Co., Ltd. ねじ溝加工方法
EA013162B1 (ru) 2005-04-18 2010-02-26 Микромет Аг Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека
RU2447085C2 (ru) * 2005-05-18 2012-04-10 МорфоСис АГ Анти-gm-csf антитела и их применение
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
JP5210889B2 (ja) * 2006-02-08 2013-06-12 モルフォテック、インク． 抗原性ｇｍ−ｃｓｆペプチドおよび抗ｇｍ−ｃｓｆ抗体
EP2101780B1 (en) 2006-11-21 2013-10-09 Kalobios Pharmaceuticals, Inc. Methods of treating chronic inflammatory diseases using a gm-csf antagonist
US8398972B2 (en) 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
DK2215119T3 (da) 2007-11-13 2013-02-04 Evec Inc Monoklonale antistoffer der binder til HGM-CSF og medicinske sammensætninger omfattende de samme.

Also Published As

Publication number Publication date
TW200927760A (en) 2009-07-01
EP2535353A8 (en) 2013-04-03
EP2559706A1 (en) 2013-02-20
EP2215119B1 (en) 2012-12-26
CN101970489A (zh) 2011-02-09
SI2215119T1 (sl) 2013-04-30
ZA201003467B (en) 2012-01-25
ME01005B (me) 2012-10-20
CA2705539A1 (en) 2009-05-22
US20140205611A1 (en) 2014-07-24
PT2215119E (pt) 2013-02-11
US20110182905A1 (en) 2011-07-28
IL205576A0 (en) 2010-11-30
RU2517596C2 (ru) 2014-05-27
TWI434854B (zh) 2014-04-21
NZ597023A (en) 2013-07-26
EP2215119A1 (en) 2010-08-11
MX2010005291A (es) 2010-11-12
TW201206955A (en) 2012-02-16
RU2013141223A (ru) 2015-03-20
US8679502B2 (en) 2014-03-25
CL2008003361A1 (es) 2010-02-05
MA31899B1 (fr) 2010-12-01
WO2009064399A1 (en) 2009-05-22
AR069290A1 (es) 2010-01-13
KR20100102108A (ko) 2010-09-20
EP2535353A1 (en) 2012-12-19
ECSP10010251A (es) 2010-08-31
PL2215119T3 (pl) 2013-06-28
SG176499A1 (en) 2011-12-29
HK1146729A1 (en) 2011-07-08
ES2401536T3 (es) 2013-04-22
AU2008321429A1 (en) 2009-05-22
PE20091420A1 (es) 2009-10-17
CN104072613A (zh) 2014-10-01
NZ586027A (en) 2012-01-12
UY31466A1 (es) 2009-07-17
CO6382188A2 (es) 2012-02-15
TN2010000210A1 (en) 2011-11-11
RS52713B (en) 2013-08-30
HRP20130204T1 (hr) 2013-04-30
CN101970489B (zh) 2014-06-11
BRPI0820530A2 (pt) 2015-06-16
RU2010123693A (ru) 2011-12-20

Similar Documents

Publication Publication Date Title
DK2215119T3 (da) Monoklonale antistoffer der binder til HGM-CSF og medicinske sammensætninger omfattende de samme.
CY2019004I2 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
DK3184546T3 (da) Antistoffer, der binder human cgrp-receptor
HRP20150074T1 (hr) Humana antitijela koja se vežu za mezotelin i njihove uporabe
IL225460B (en) Antibodies that bind to p4d12191, preparations containing them and their uses
ZA201003496B (en) Monoclonal antibody capable of binding to anexelekto,and use thereof
DK2185574T3 (da) Antistoffer og relaterede molekyler, der bindes til 24P4C12-proteiner
IL211284A0 (en) Antibodies binding ccr2, compositions comprising the same and uses thereof
IL234081B (en) Antibody binds cd3–epsilon in different species
FI20070853A0 (fi) Glykaania sitovat monoklonaaliset vasta-aineet
DK3360571T3 (da) Antistoffer, der binder til et intracellulært PRL-1- eller PRL-3-polypeptid
BRPI0817250A2 (pt) Anticorpo anti-receptor da il-6.
IL186486A0 (en) Antibodies which bind to gm-csf and pharmaceutical compositions containing the same
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
DK2132230T3 (da) Apoptotiske anti-ige-antistoffer, der binder det membranbundne ige
IL201340A (en) Antidote 3dc - epsilon in various species
BRPI0815075A2 (pt) Aglutinantes
BRPI0914763A2 (pt) composição aglutinante
IL198592A0 (en) Tes7 and antibodies that bind thereto
IL221205A0 (en) Antibody drug conjugates (adc) that bind to 161p2f10b proteins, compositions comprising the same and uses thereof
SI2510011T1 (sl) Monoklonska protitelesa, ki veĹľejo B7H6 in njihova uporaba
BRPI0814111A2 (pt) Anticorpo monoclonal citotóxico anticâncer
HK1153502A1 (en) Anti-bst2 antibody bst2
DK1871804T3 (da) Antistoffer, der binder CCX-CKR2
BRPI0814116A2 (pt) Anticorpo monoclonal citotóxico anticâncer